Oct. 20, 2014Products
Announcement of termination of co-promotion of anti-depressant, Paxil CR Tablets
GlaxoSmithKline K.K. (President: Philippe Fauchet, Head Office: Shibuya-ku, Tokyo) and Sumitomo Dainippon Pharma Co., Ltd. (President: Masayo Tada, Head Office: Chuo-ku, Osaka) announced today that the companies have reached an agreement to terminate the co-promotion of GlaxoSmithKline K.K’s anti-depressant Paxil® CR Tablets 12.5mg and Paxil® CR Tablets 25mg (paroxetine hydrochloride hydrate, hereinafter referred to as Paxil® CR, CR stands for Controlled Release) as of end of December 2014.
The co-promotion activity by the 2 companies was started in April 2012, with the objective of accelerating the providing and collecting of proper prescribing information on Paxil® CR, so that this medication can support patients suffering from depression.
From January 2015, GlaxoSmithKline K.K. will solely be responsible for providing information on Paxil® CR.
GlaxoSmithKline K.K. and Sumitomo Dainippon Pharma Co., Ltd. will continue to contribute to medicine through providing and collecting of proper prescribing information of individual products.